Alphatec Spine reports 1Q19 revenue of USD $24.6MM, +15.3% vs. 1Q18.
- Continued to update legacy-heavy portfolio with three new releases: the IdentiTi ACDF, the IdentiTi PLIF system and AlphaGRAFT DBM Fiber
- Received FDA clearance for SafeOP neuromonitoring system
- New products contributed 22% of U.S. revenue for the quarter
- Sales from strategic distributors comprised 84% of U.S. revenue for the quarter, up from 72% the prior year
- Compared to 1Q18, revenue per distributor increased 30% and revenue per case increased 13%
- Non-strategic international supply agreements are winding down, per leadership
Segment sales and growth on an as-reported basis ($MM):
1Q19 | 1Q18 | $ Chg | % Chg | |
Spine | $22.3 | $19.3 | $2.9 | 15.2% |
Orthobiologics | $2.3 | $2.0 | $0.3 | 16.5% |
Total | $24.6 | $21.3 | $3.3 | 15.3% |
Revenue by geographic region ($MM):
Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
US | $23.0 | $19.2 | $3.8 | 19.6% |
Ex-US | $1.6 | $2.1 | -$0.5 | -23.8% |
Total | $24.6 | $21.3 | $3.3 | 15.3% |
Net earnings ($MM):
1Q19 | Amount | % of Sales |
Sales | $24.6 | |
Cost of Sales | -$8.0 | 32.5% |
Selling and Admin | -$21.0 | 85.5% |
R & D | -$3.5 | 14.1% |
Other | -$5.1 | 20.6% |
Net Earnings | -$13.0 | -52.8% |
Sources: Alphatec Spine; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Alphatec Spine reports 1Q19 revenue of USD $24.6MM, +15.3% vs. 1Q18.
Continued to update legacy-heavy portfolio with three new releases: the IdentiTi ACDF, the IdentiTi PLIF system and AlphaGRAFT DBM Fiber
Received FDA clearance for SafeOP neuromonitoring system
New products contributed 22% of U.S. revenue for the...
Alphatec Spine reports 1Q19 revenue of USD $24.6MM, +15.3% vs. 1Q18.
- Continued to update legacy-heavy portfolio with three new releases: the IdentiTi ACDF, the IdentiTi PLIF system and AlphaGRAFT DBM Fiber
- Received FDA clearance for SafeOP neuromonitoring system
- New products contributed 22% of U.S. revenue for the quarter
- Sales from strategic distributors comprised 84% of U.S. revenue for the quarter, up from 72% the prior year
- Compared to 1Q18, revenue per distributor increased 30% and revenue per case increased 13%
- Non-strategic international supply agreements are winding down, per leadership
Segment sales and growth on an as-reported basis ($MM):
1Q19 | 1Q18 | $ Chg | % Chg | |
Spine | $22.3 | $19.3 | $2.9 | 15.2% |
Orthobiologics | $2.3 | $2.0 | $0.3 | 16.5% |
Total | $24.6 | $21.3 | $3.3 | 15.3% |
Revenue by geographic region ($MM):
Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
US | $23.0 | $19.2 | $3.8 | 19.6% |
Ex-US | $1.6 | $2.1 | -$0.5 | -23.8% |
Total | $24.6 | $21.3 | $3.3 | 15.3% |
Net earnings ($MM):
1Q19 | Amount | % of Sales |
Sales | $24.6 | |
Cost of Sales | -$8.0 | 32.5% |
Selling and Admin | -$21.0 | 85.5% |
R & D | -$3.5 | 14.1% |
Other | -$5.1 | 20.6% |
Net Earnings | -$13.0 | -52.8% |
Sources: Alphatec Spine; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.